Welcome to ADVAC

ADVAC is a two-week training programme for decision-makers, including academia, industry, governmental and non-governmental agencies. The Course aims to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the various aspects of vaccinology (immunology, vaccine development, clinical trials, regulatory processes, vaccine-specific issues including new vaccines, vaccination strategies and policies, programme implementation, humanitarian emergencies, social, economic, political and ethical issues, financing, and communications…).

Read more

ADVAC - Advanced Course of Vaccinology

The 22nd ADVAC will take at Les Pensières, Annecy, France
from 9 to 20 May 2022.

The website is now closed for applications to the Course in 2022
and will reopen on 1 July 2022 for applications to the Course in 2023.

Tarik Derrough

Tariq Derrough

European Centre for Disease Prevention and Control (ECDC)

Tarik Derrough has been employed since 2010 within the vaccine-preventable diseases programme at the European Centre for Disease Prevention and Control in Stockholm, Sweden. He is now a Principal Expert serving the vaccine programme at both technical and strategic level. He has led numerous projects in the areas of surveillance, epidemic intelligence, outbreak response and scientific advice. In his current position, he is coordinating an EU-wide collaboration of national immunisation technical advisory groups (NITAGs) with the aim to share information between such national committees as well as facilitating the joint generation and exchange of scientific evidence. This also includes coordination and collaboration with other international and national public health agencies. Since the onset of the COVID-19 pandemic, Tarik has been involved in the ECDC COVID-19 crisis team in support of vaccination, epidemic intelligence, response and preparedness activities. Prior to joining ECDC, Tarik worked for 10 years in activities including vaccine safety, phase III and phase IV clinical trials of existing and new vaccines. Tarik is a pharmacist by training before specialising in epidemiology and public health.
Declarations of Conflict of Interest

Melanie Saville

Melanie Saville

Coalition for Epidemic Preparedness Innovations (CEPI)

Melanie Saville MB BS
Director Vaccine Research and Development, CEPI
Melanie Saville joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017. She is the Director of Vaccine Research and Development, and leads the technical teams supporting the vaccine development and enabling science projects funded by CEPI and is the R&D and Manufacturing workstream leader for COVAX. Melanie is a physician specialized in virology with 20 yrs of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines for seasonal and pandemic influenza, pediatric combinations, Rabies, Japanese Encephalitis and Dengue vaccine in Europe, US and the international area.
Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a master's in medical Virology from Imperial College, London. In the vaccine industry, Melanie has held positions of increasing responsibility in research and development working for Wyeth, Sanofi Pasteur and Janssen vaccines and prevention.
Declarations of Conflict of Interest

Kathleen Neuzil

Kathleen Neuzil

Director - Center for Vaccine Development and Global Health, 
University of Maryland School of Medicine
United States

Dr. Kathleen Neuzil is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology. Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases, yielding high-profile publications that inform policy decisions and public health actions. Dr. Neuzil's work has spanned dozens of low-resource countries with multiple vaccines, including influenza, rotavirus, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, and most recently, COVID-19 vaccines. Dr. Neuzil is central to the domestic and global response to COVID. As a co-PI of the NIH-funded Leadership Group for the Vaccine and Treatment Evaluation Unit network, Dr. Neuzil is part of the strategic team evaluating COVID vaccines and therapeutics in the US and was part of the study team who designed the first COVID-19 clinical vaccine trial in the US. The CVD is likewise participating in COVID treatment and post-exposure prophylaxis trials. Dr. Neuzil also directs TyVAC, the Typhoid Vaccine Acceleration Consortium, with the goal to accelerate the introduction of typhoid conjugate vaccines into low-resource countries. She has more than 230 scientific publications on vaccines and infectious diseases. Dr. Neuzil's research capabilities are complimented by 20 years of involvement in domestic and international policy, including past membership on the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization.
Declarations of Conflict of Interest

Ananda Bandyopadhyay

Ananda Bandyopadhyay

Deputy Director - Polio

Bill & Melinda Gates Foundation

Dr. Ananda Bandyopadhyay is a medical epidemiologist with experience in global health, infectious disease epidemiology and vaccine research. Ananda grew up in Kolkata, India and completed his medical graduation from Calcutta National Medical College & Hospital (2005) with a gold medal and several honors certificates. He received his Master of Public Health (MPH) degree in Global Health from Harvard School of Public Health (2010). In his professional career spanning more than 15 years, Ananda has worked in diverse settings and has contributed to disease control initiatives across the globe. He worked as a Surveillance Medical Officer with National Polio Surveillance Project, WHO and contributed to India’s polio elimination effort and measles surveillance initiatives. Based out of Seattle, United States, Ananda in his current role as a Deputy Director at the Bill and Melinda Gates Foundation coordinates global research to facilitate polio eradication. His work on clinical development of novel vaccines and polio endgame vaccination schedules along with his research to expand and enhance polio environmental surveillance have been impactful in global policy formulation and have been published in leading peer-reviewed journals. Ananda is associated with advanced degree programs in public health and vaccinology in several globally renowned teaching venues as a guest faculty.  

Declarations of Conflict of Interest

Emily Erbelding

Emily Erbelding

Director of the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)

Emily Erbelding, M.D., M.P.H. Dr. Emily Erbelding is the Director of the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). She is responsible for the strategic and scientific vision for DMID's complex national and international research program. DMID supports basic, preclinical, and clinical investigations into the causes, diagnosis, treatment, and prevention of a broad range of pathogens, including those related to biodefense and emerging infectious diseases.

The DMID funds a robust extramural research portfolio in basic, translational, and clinical research with a budget of over $1.6M annually.

Prior to joining DMID in 2017, Dr. Erbelding served as deputy director of the Division of AIDS at NIAID, spent 14 years on the faculty of the Johns Hopkins University School of Medicine, in the Division of Infectious Diseases, and was the Director of Clinical Services for the Baltimore City Health Department STD/HIV program.

Dr. Erbelding received her Bachelor's and Master's degrees from Cornell University and her medical degree from Indiana University School of Medicine.

She completed her residency in internal medicine at Northwestern University Medical Center and her fellowship in infectious diseases at Johns Hopkins.

Declarations of Conflict of Interest

Melinda Wharton

wharton melinda

Captain, United States Public Health Service (USPHS) Acting Director, National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention
United States Public Health Service (USPHS) and National Center for Immunization and Respiratory Diseases
United States

Dr. Melinda Wharton currently serves as the Acting Director for the National Center for Immunization and Respiratory Diseases. Prior to this appointment, Dr. Wharton served as the Acting Director of the Immunization Safety Office (ISO), where she provided overall leadership for the office and help to guide ISOs transition from CDCs Office of the Director to the Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases.

She has previously managed CDC programs in infant immunization and childhood vaccine-preventable diseases, served as Division Director for epidemiology and surveillance, and then as Deputy Director in the former National Immunization Program (NIP). Since 2006 she has served as Deputy Director of the National Center for Immunization and Respiratory Diseases. She has worked extensively on issues related to vaccine policy, vaccine safety science, and public health response. Dr. Wharton holds an M.D. from Harvard Medical School and an M.P.H. from Johns Hopkins Bloomberg School of Public Health. She completed her internship and residency in internal medicine at the University of Michigan Medical Center, in Ann Arbor, Michigan, and her infectious diseases fellowship at the Duke University Medical Center, in Durham, North Carolina. Dr. Wharton was commissioned as a CDC Epidemic Intelligence Service Officer in 1986 and was assigned to the Tennessee Department of Health and Environment in Nashville, TN. In 1989, she joined CDC as a medical epidemiologist in the Epidemiology Program Office.

She joined the National Immunization Program in 1992, holding chief positions in the Infant Immunization Section, Surveillance, Investigations, and Research Branch, and the Child Vaccine Preventable Diseases Branch, Epidemiology and Surveillance Division, and serving as Director, Epidemiology and Surveillance Division. In January 2004 she became Acting Deputy Director of NIP.Dr. Wharton has authored or co-authored more than 80 scientific journal articles, book chapters, and CDC publications, including MMWR articles.

Declarations of Conflict of Interest

Hanna Nohynek

nohynek hanna

National Institute for Health and Welfare
Helsinki - Finland

Hanna Nohynek completed her medical studies, PhD and international health competence in Helsinki, Finland. She is working as Vaccine Safety Officer at the National Institute for Health and Welfare (THL, former National Public Health Institute, KTL), Finland. She is the scientific coordinator of the ARIVAC consortium (www.sph.uq.edu.au/arivac and www.ktl.fi/arivac). She is Fellow of the Faculty of Travel Medicine of the Royal Society of Physicians and Surgeons of Glasgow. She practices at two private travel health clinics in Helsinki. Her PhD work was on development and evaluation of methods for identifying the aetiology of childhood pneumonia, which she studied in Finland, Russia, and the Philippines. In collaboration with the Research Institute for Tropical Medicine in the Philippines, she coordinated several phase II trials (Hib, meningococcal, PCV among infants, and Pnc polysaccharide among pregnant mothers and infants), and a major phase III trial of 11PCV against childhood pneumonia on the island of Bohol. Her current research interests include vaccine safety, especially registry based epidemiological studies, ARI etiology and disease burden, Hib, Pnc and meningococcal CV, new vaccines against tuberculosis, vaccine related adverse events, herd immunity, policy and decision making, evidence based evaluation of introduction of new vaccines into national programmes, travel health, bioethics related to clinical trials and international health research. Her publications include > 60 articles, chapters and books. She teaches nationally and internationally, and has guided several elective, graduate, and PhD students.She is the secretary of the Finnish Narcolepsy Task Force studying the association of pandemic vaccine and narcolepsy. She also is a member of the THL Advisory Board for Vaccines, and has served in expert committees evaluating introduction of PCV and rota virus vaccine in Finland. She is Editor in Chief of the Finnish Vaccinators Manual and the Finnish International Health Manual (www.thl.fi). She serves as technical advisor to EU (DG Research and SanCo), WHO (Global Advisory Committee on Vaccine Safety, and others), GAVI, SIDA, the Finnish Ministry of Foreign Affairs and Encorium. She was chairman of EPIET and member of EDCTP 2002-3. She belongs to the faculty of the Advanced Course in Vaccinology since its beginning in 2000 and to the ECDC contracted vaccine epidemiology module, and the Finnish Diploma Course on Global Health.
Declarations of Conflict of Interest



Mark Miller

marc miller

National Institutes of Health
United States

Mark Miller, MD is formerly the Fogarty international Centers Associate Director for Research and Founding Director of the Division of International Epidemiology and Population Studies at the National Institutes of Health (NIH), Bethesda, MD. He previously served as a Medical Officer on the Children's Vaccine Initiative for the World Health Organization and the Centers for Disease Control and Prevention (CDC), and Medical Epidemiologist for the CDC National Immunizations Program and Epidemiology Program Office. He has conducted laboratory, translational and policy analytical research in bacterial and viral vaccine discovery/development and deployment at the international and national levels. Dr Miller led several multi-national studies including the Malnutrition and Enteric Disease Study (MAL-ED) and the Multinational Influenza Seasonal Mortality Study (MISMS) and has received over $65 million of private and government research grants. His biomedical research has also led to a patent of a novel method to formulate recombinant influenza vaccines and a common protein influenza vaccine. He has served as a member of many professional societies and steering committees, including the US Department of Health and Human Services Secretary's Advisory Council on Public Health Preparedness and several National Science Foundation and NIH task forces. He has presented and consulted nationally and internationally for organizations including the World Health Organization, UNICEF, US Agency for International Development, the Pan American Health Organization, and the World Bank. Current research interests include the integration of multi-disciplinary quantitative data to help inform population based public health outcomes. This includes the incorporation of historical vital statistics, biomedical, demographic, economic and environmental datasets of various spatial and temporal resolution to help understand the role of microbial organisms and human populations in the fields of infectious diseases, child growth and cognitive development. Most studies are conducted in diverse populations throughout the world.

Dr. Miller has received numerous awards, including the Distinguished Service Medal, from the US Public Health Service. He has published over 160 scientific articles in the peer-reviewed literature and numerous book chapters.
Declarations of Conflict of Interest



Roger Glass

glass roger

Director, Fogarty International Center
Associate Director for International Research, NIH National Institutes of Health
Bethesda, Maryland, USA

Dr. Glass was named Director of the Fogarty International Center and Associate Director for International Research by NIH Director Elias A. Zerhouni, M.D., on March 31, 2006.

Dr. Glass graduated from Harvard College in 1967, received a Fulbright Fellowship to study at the University of Buenos Aires in 1967, and received his M.D. from Harvard Medical School and his M.P.H. from the Harvard School of Public Health in 1972. He joined the Centers for Disease Control and Prevention in 1977 as a medical officer assigned to the Environmental Hazards Branch. He was a Scientist at the International Center for Diarrheal Disease Research in Bangladesh from 1979-1983 and returned to Sweden where he received his doctorate from the University of Goteborg. In 1984, he joined the National Institutes of Health Laboratory of Infectious Diseases, where he worked on the molecular biology of rotavirus. In 1986, Dr. Glass returned to the CDC to become Chief of the Viral Gastroenteritis Unit at the National Center for Infectious Diseases.

Dr. Glass's research interests are in the prevention of gastroenteritis from rotaviruses and noroviruses through the application of novel scientific research. He has maintained field studies in India, Bangladesh, Brazil, Mexico, Israel, Russia, Vietnam, China and elsewhere. His research has been targeted toward epidemiologic studies to anticipate the introduction of rotavirus vaccines. He is fluent and often lectures in five languages.

Dr. Glass has received numerous awards including the prestigious Charles C. Shepard Lifetime Scientific Achievement Award presented by the CDC in recognition of his 30-year career of scientific research application and leadership, the Dr. Charles Merieux Award from the National Foundation for Infectious Diseases for his work on rotavirus vaccines in the developing world, Dr. Glass is also the recipient of the Albert B. Sabin Gold Medal Award, Georgetown University's Cura Personalis Award, Research!America's Geoffrey Beene Builders of Science Award, Rice University's Rice 360 Institute for Global Health Award, and the Jimmy and Rosalynn Carter Humanitarian Award from the National Foundation for Infectious Diseases. He is a member of the Institute of Medicine of the U.S. National Academy of Medicine. Dr. Glass has co-authored more than 600 research papers and chapters.
He is married to Barbara Stoll, M.D., the H. Wayne Hightower Distinguished Professor in the Medical Sciences and Dean of the University of the Texas Medical School at Houston, and the father of three children: Nina, Michael and Andy Glass.

Declarations of Conflict of Interest

Annelies Wilder-Smith

levine orin

Fondation Mérieux

Annelies Wilder-Smith is Professor of Emerging Infectious Diseases at the London School of Hygiene and Tropical Medicine. She also serves as Consultant to the Initiative of Vaccine Research at the World Health Organization, Geneva, Switzerland, where she is responsible for the SAGE deliberations on the use of the first dengue vaccine, second-generation dengue vaccines, as well as the use of fractional yellow fever vaccination, and developing a technical roadmap for Zika vaccines. A world renowned expert in travel and tropical medicine, she is the Immediate Past President of the International Society of Travel Medicine (ISTM), Past-President of the Asia Pacific Society of Travel Medicine, and Editor-in-Chief of the Journal of Travel Medicine.

Her special research interests include vaccine preventable and emerging infectious diseases, in particular dengue, Zika, yellow fever, chikungunya, influenza and meningococcal disease. With a career spanning almost three decades, she has led and co-led various vaccine trials, published more than 260 scientific papers, edited and co-edited textbooks and travel medicine books, served on various editorial boards and scientific committees, including being editorial consultant to The Lancet. She is the Principal Investigator of an EU funded international consortium called "ZikaPLAN" (https://zikaplan.tghn.org/), and recently completed another 4 year research project on dengue, also funded by the European Commission.

Declarations of Conflict of Interest

Martin Friede

friede martin

Scientific Officer
World Health Organization Initiative for Vaccine Research

Martin Friede is the scientific officer responsible for vaccine delivery systems within the Initiative for Vaccine Research (IVR) at the World Health Organization in Geneva, Switzerland. In this position he is the WHO focal point for matters related to the development of technologies to improve vaccines including adjuvants, stabilization methods needle-free vaccine delivery systems.Prior to joining WHO Dr Friede held several positions in the vaccine industry: He was Vice President of Development for Apovia Inc. a Californian vaccine development company, prior to which he was responsible for vaccine formulation and vaccine delivery research at Smithkline Beecham Biologicals (now GlaxoSmithKline).Martin Friede received his PhD in biochemistry from the University of Cape Town in South Africa.
Declarations of Conflict of Interest



Adam Finn

finn adam

David Baum Professor of Paediatrics and Director
Dept Clinical Sciences at University of Bristol and South West Medicines
United Kingdom

Adam Finn is Professor of Paediatrics at the University of Bristol and honorary consultant in paediatric infectious diseases and immunology at Bristol Royal Hospital for Children. He is Clinical Research Lead - Children, Genetics, Haematology, Reproductive Health and Childbirth for the NIHR Clinical Research Network: West of England and heads the Bristol Children's Vaccine Centre. He leads the paediatric immunology and infectious diseases clinical service for Bristol and the South West region. His main recent research interests continue to relate to elucidation of the nature of naturally acquired mucosal immunity to pneumococcus, meningococcus and other respiratory bacteria and development of tools to assess human immune responses to candidate vaccine antigens. He also leads and supports numerous clinical trials of drugs and medicines in children.
Declarations of Conflict of Interest

Michael Makanga

Michael Makanga
European and Developing Countries Clinical Trials Partnership
Executive Director
Dr. Michael Makanga, MD PhD FRCP: EDCTP Executive Director. Dr. Makanga is a clinician-scientist with 25 years of professional experience of working on health and poverty-related infectious diseases in Africa. This includes 21 years of work experience on drugs and vaccines product development, and clinical regulatory activities. He holds a Medical Degree from Makerere University, Uganda, and has been in various clinical and research positions before and after undertaking a Master's Degree at the University of Liverpool, and a PhD Clinical Pharmacology at the Liverpool School of Tropical Medicine, United Kingdom. He is also a Fellow of the Royal College of Physicians of Edinburgh, Scotland.

Before joining EDCTP, Dr Makanga was first in clinical practice and academia, and later clinical research and research management. He joined EDCTP in 2004 and has served in different progressive management positions prior to his current appointment. During the last 15 years at EDCTP, he has built up significant experience in global health, research for health capacity development, quality assurance, project management and evaluation, health and research management as well as diplomacy and engagement with policy makers, health and regulatory authorities in sub-Saharan Africa and Europe. Moreover, he has served in various scientific and policy advisory boards for international product development, philanthropic organisations, World Bank and pharmaceutical companies involved in developing medicinal products for poverty related and neglected diseases.

Declarations of Conflict of Interest

Anna Durbin

juliet bryant

Johns Hopkins Bloomberg School of Public Health

Dr. Durbin received her Bachelor of Science in Pharmacy from the University of Michigan, Ann Arbor Michigan and her M.D. from Wayne State University in Detroit Michigan. She is certified in the specialties of Internal Medicine and Infectious Diseases. Following her fellowship in infectious diseases, Dr. Durbin became a Medical Officer at the Laboratory of Infectious Diseases at the National Institutes of Health where she spent 5 years using recombinant DNA technology to develop novel live attenuated respiratory virus vaccines. She left the NIH to become a tenure-track faculty in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health where she is currently as associate professor.

She is the Principal Investigator of a National Institutes of Health contract to evaluate novel malaria vaccines and is the co-principal investigator for a contract to evaluate vaccines and antimicrobials in adults and pediatric subjects. She has served as the Principal Investigator for numerous clinical trials evaluating the safety and immunogenicity novel live attenuated dengue vaccine candidates. These trials have led to the identification of a live attenuated tetravalent dengue vaccine that is currently being evaluated in in flavivirus-naïve and flavivirus-experienced volunteers in Brazil and Thailand and has begun Phase 3 efficacy trials in Brazil. She has, in collaboration with NIH scientists, developed a controlled dengue human infection model (CHIM) to down-select candidate dengue vaccines prior to the initiation of large-scale efficacy trials in endemic areas. She has served on FDA and WHO vaccine advisory committees.

Dr. Durbin received a National Institutes of Health Merit Award in 2005, a National Institutes of Health Director's Award in 2011 and the Instituto Butantan medal, Sao Paulo Brazil, in 2013. She has published more than 70 peer-reviewed papers.

Declarations of Conflict of Interest

Edwin Asturias

edwin j asturias

Associate Professor of Pediatrics
University of Colorado School of Medicine
United States

Edwin J. Asturias is currently the Jules Amer Chair in Community Pediatrics and an Associate Professor of Pediatric Infectious Diseases and Epidemiology at the University of Colorado School of Medicine and the Colorado School of Public Health. He is the Director for Latin America at the Center for Global Health. A native of Guatemala where he trained as an MD (University of San Carlos, 1989) and was boarded in pediatrics and infectious diseases at UC and Johns Hopkins University School of Medicine.

Before moving to Colorado, he was an associate scientist from Johns Hopkins Bloomberg School of Public Health based in Guatemala for 13 years. His career has focused on establishing the epidemiology of vaccine preventable diseases in low and middle income countries of Central America, determining the factors that influence the introduction of new, and exploring the emergence of new infectious diseases. He has served as a member and vice chair of the Global Advisory Committee of Vaccine Safety from WHO, and has presided several data safety monitoring boards. His research interest is now focused on vaccine safety, immunization schedules, and the application of innovative technologies to optimize immunization for children.

Declarations of Conflict of Interest

Claire-Anne Siegrist

siegrist claire anne

Executive Director of ADVAC
Professor of Vaccinology, Director of the Center for Vaccinology, University and University Hospitals of Geneva

Claire-Anne Siegrist is Professor of Vaccinology at the University of Geneva (Switzerland), Director of the Center for Vaccinology at the University and the University Hospitals of Geneva. After her MD graduation, she trained in Geneva and in the INSERM-CNRS Immunology Center of Marseille-Luminy, France, where she studied the mechanisms of antigen presentation to the immune system and obtained an Advanced Diploma (DEA) in Immunology from Aix-Marseille II University. After her return to Geneva, Dr Siegrist continued her molecular and cellular immunology studies on the regulation of MHC molecules and their influence on immune responses.

In 1994, Dr Siegrist initiated a new research group on Vaccinology and Neonatal Immunology. With her thesis on Vaccination in Early Life, she obtained her PD accreditation in 1998. She was nominated as Professor of Vaccinology at the University of Geneva in 1999.Prof. Siegrist was nominated in 2002 at the Swiss Academy of Medicine, and in 2004 at the Swiss National Research Foundation. In 2005, she received the Bill Marshall Award from the European Society for Paediatric Infectious Diseases and in 2017 the Nessim Habiff Global Prize. Professor Siegrist serves or as served as an expert in Vaccinology on numerous national and international Advisory Committees. She was the President of the Swiss Advisory Committee for Immunizations (CFV/EKIF) between 2004 and 2014, a member of the UK Joint Committee for Vaccination and Immunization (JCVI) in 2008-2016 and of the WHO Strategic Advisory Group of Experts (SAGE) in 2010-2016. She has contributed to a large number of original scientific publications in the field of vaccine immunology. Prof. Siegrist is an outstanding teacher who is invited worldwide to give seminars and conferences on vaccine immunology and/or vaccine safety issues, being widely appreciated for her capacity of making complex issues appear crystal-clear.

Prof. Siegrist is also directly involved in multiple activities aiming at improving training and information of health professionals on vaccine related issues, including the setting up of InfoVac (www.infovac.ch), a network for the information of health professionals on all issues regarding immunization. The quality and the objectivity of her engagement for the promotion of evidence-based vaccinology is recognized and appreciated worldwide.

Declarations of Conflict of Interest

Stanley Plotkin

plotkin s

Consultant and Emeritus Professor of the University of Pennsylvania
Vaxconsult, LLP
United States

Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. He maintained laboratories at both CHOP and Wistar. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught (now called Sanofi Pasteur), where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. He left France in 1998, and is now consultant to many vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult. He also continues to teach at the University of Pennsylvania.

Dr. Plotkin attended New York University, where he received a B.A. degree, and then the State University of New York Medical School in Brooklyn, where he received an M.D. degree in 1956. His subsequent career included internship at Cleveland Metropolitan General Hospital under Fred Robbins, residency in pediatrics at the Children's Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service. While in EIS in the 1950s he worked on the development of oral polio vaccine and on the efficacy of a vaccine against inhalation and cutaneous anthrax.

He has been chairman of both the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin received the Bruce Medal in Preventive Medicine of the American College of Physicians, the Distinguished Physician Award of the Pediatric Infectious Diseases Society, the Clinical Virology Award of the Pan American Society for Clinical Virology, the Richard Day Master Teacher in Pediatrics Award of the Alumni Association of New York Downstate Medical College, and the Marshall Award of the European Society for Pediatric Infectious Diseases. In June 1998, he received the French Legion of Honor Medal; in June 2001, the Distinguished Alumnus Award of the Children's Hospital of Philadelphia, in September 2006 the gold medal from the same hospital; the Sabin Gold Medal in May 2002, in September 2004 the Fleming (Bristol) Award of the Infectious Diseases Society of America, in May 2007 the medal of the Fondation Mérieux, in 2009 the Finland Award of the National Foundation for Infectious Diseases and the Hilleman Award of the American Society for Microbiology, and in 2013 the Career Achievement Award from the Association for Clincal and Translational Medicine, as well as the Caspar Wistar Medal of the Wistar Institute of Biological Research In 2014 he received the Charles Mérieux Award of the National Foundation for Infectious Diseases and the Sheikh Hamdan (Dubai) Award for Medical Sciences. He was elected to the Institute of Medicine of the National Academy of Sciences in 2005, to the French Academy of Medicine in 2007, to the French Academy of Pharmacy in 2013, and to the Thai Pediatric Infectious Diseases Society in 2015. Dr. Plotkin is the Founder and a Fellow of the Pediatric Infectious Diseases Society. He is also a Fellow of the Infectious Diseases Society of America, of the International Society for Vaccines, the American Academy of Pediatrics and the College of Physicians of Philadelphia. Dr. Plotkin holds honorary doctoral degrees from the University of Rouen (France) and the Complutense University of Madrid (Spain). He is on the board of the Rostropovich Foundation. Named lectures in his honor have been established at the Pediatric Academic Societies annual meeting, at the International Advanced Vaccinology Course in Annecy, France, and at the DNA Vaccines Society. A professorship in his name was established at the Children's Hospital of Philadelphia. His bibliography includes nearly 800 articles and he has edited several books including the standard textbook on vaccines, now in its 7th edition and now titled "Plotkin's Vaccines." In 2000, Plotkin proposed and helped organize an Advanced Course in Vaccinology at the Fondation Mérieux, now in its 19th year. In 2015, in the New England Journal of Medicine, he proposed an international fund for development of vaccines against emerging diseases, which now exists as the Coalition for Epidemic Preparedness and Innovation. He developed the rubella vaccine now in standard use throughout the world, is codeveloper of the pentavalent rotavirus vaccine, and has worked extensively on the laboratory development and application of other vaccines including anthrax, oral polio, rabies, varicella, pertussis, Lyme disease and cytomegalovirus.
Declarations of Conflict of Interest

Paul-Henri Lambert

lambert p a

Centre of Vaccinology, Department of Pathology and Immunology at University of Geneva


Paul-Henri Lambert, MD, is associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is particularly interested in vaccination strategies and evaluation of adverse effects. Between 2000 and 2018, he served as Director of the International Advanced Course of Vaccinology (ADVAC) organised under the auspices of the Fondation Mrieux and University of Geneva.

He is a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI) and chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS). Paul Henri Lambert is a native of Belgium where he was boarded in Internal Medicine (University of Liege). He joined Frank Dixon at Scripps Institute, La Jolla, California, for his training then moved to University of Geneva Medical School where he became professor in the Departments of Medicine and of Pathology.

His research activities lead him to decipher immunological mechanisms involved in autoimmune and immune complex-mediated diseases, in the pathogenesis of malaria and in new strategies to optimise vaccine immunogenicity. In 1987, he was appointed as chief Microbiology and Immunology at the World Health Organization and in 1994, Chief, Vaccine Research and Development, WHO Global Programme for Vaccines and Immunisation.

He was then deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries. Paul-Henri Lambert is author or co-author of 436 publications, member of several international scientific boards, foreign member of the Royal Academy of Medicine in Belgium and Fellow of the American Association for the Advancement of Science.

Declarations of Conflict of Interest

Philippe Duclos

duclos philippe

Director ADVAC
University of Geneva

Philippe Duclos holds a Doctorate in Veterinary Medicine and a PhD from the Claude Bernard University, Lyon, France. He started his career as Associate Professor in the Department of Infectious Diseases and Zoonotic Diseases at the Veterinary School in Lyon.

In 1986, he moved to the US Centers for Disease Control and Prevention studying ways to mitigate the impact of disasters. For the last 30 years, his work focused on immunization. He worked for the Canadian Federal Government, at the Laboratory Centre for Disease Control, then in charge of the Division of Immunization. He initiated the active paediatric surveillance network based in paediatric hospitals (IMPACT) and the Canadian Paediatric Surveillance Program.

In 1998 he joined the World Health Organization. First leading the Immunization Safety Priority Project, he established the Global Advisory Committee on Vaccine Safety and was at the inception of the Brighton Collaboration. Between 2005 and 2017 he then served as Executive Secretary for the Strategic Advisory Group of Experts on immunization and was in charge of the development of global immunization policy recommendations and the production of the WHO vaccine position papers. He recently retired from WHO.

He held an adjunct professorship in the Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa until 1 September 2017. He is currently affiliated with the University of Geneva and serves as Director of ADVAC. He is the author or co-author of over 250 publications and hundreds of invited presentations at international conferences.

Declarations of Conflict of Interest



    Discussion topic:
    The impact of COVID on pneumococcal disease in children

    Professor Ron Dagan
    Distinguished Professor of Pediatrics and Infectious Diseases, Soroka University Medical Center, Beer-Sheva, Israel

    Read More

    Discussion topic:
    HPV vaccination: Prospect of moving to a one and only dose schedule

    Margaret Stanley
    University of Cambridge, UK
    play webinar

    Read More
  • Second Workshop of the Global Collaboration
    on Advanced Vaccinoogy Training

    On 22-24 March 2022, ADVAC organized the 2nd Global Workshop on Advanced Vaccinology Training (ICAVT) which aims to assist courses in addressing challenges in priority areas, and facilitate interactions and exchange of information.
    Leaders of thirty-three advanced vaccinology courses were invited to meet with partners to further the aims of the International Collaboration on Advanced Vaccinology Training (ICAVT) initiated at the 1st Global Workshop on Advanced Vaccinology Training organized by ADVAC in 2018.

    Read More

    Discussion topic:
    Safety of COVID-19 Vaccines


    Rita Helfand, Chair, Global Advisory Committee on Vaccine Safety,...
    Tom Shimabukuro, Deputy Director, Immunization Safety Office,...
    play webinar

    Read More

    Discussion topic:
    Will the success of mRNA vaccine development platforms for COVID-19 lead to new platforms for old vaccines?
    Barney Graham, previously with the National Institute of Health, USA
    Philip Krause, Food & Drug Administration, USA
    play webinar

    Read More

    Discussion topic:
    COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity?
    Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI)
    Dr Jerome Kim, International Vaccine Institute, Seoul, Republic of Korea
    play webinar

    Read More


ADVAC has partnered with other training institutions to compile a listing of existing vaccinology courses available globally.

Click below to access the Global Vaccine Training e-Portal.


Login Form